UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of February 2019

001-36203
(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

On February 1, 2019, Can-Fite BioPharma Ltd. updated its corporate presentation that it intends to use in conferences and meetings with investors from time to time. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.

Exhibit Index

Exhibit No.	Description
99.1	Corporate Presentation of Can-Fite BioPharma Ltd. dated February 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 1, 2019

By: /s/ Pnina Fishman
Pnina Fishman
Chief Executive Officer

Exhibit 99.1


CAN-FITE
BioPharma Ltd.
Can-Fite Presentation
Pnina Fishman, CEO
Motti Farbstein, CFO
February 2019
Small Molecules For Big Clinical Needs™
(NYSE American: CANF) (TASE:CFBI)

Forward Looking Statement

- This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements".

- Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite's Annual Report on Form 20-F filed with the SEC on March 28, 2018 and other public reports filed with the SEC and in its periodic filings with the TASE.

- Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Company Profile

Proprietary Core Technology

- Advanced clinical stage drug development company with a compelling platform technology
- Small molecule drug products in Phase II and Phase III clinical studies ; covered by 13 Patent Families



Financial Summary

- Cash: ~$5.7M as of 9/30/2018; $2.4 Raised in January 2019
- Listed on Tel-Aviv Stock Exchange (CFBI) and NYSE American (CANF)
- Price per ADR* traded on NYSE American= $1.14 (as of 28/01/2019)
- Market Cap = ~$27 million (as of 28/01/2019)
- ~45 million ordinary shares outstanding; 65 million fully diluted

*1 ADR = 2 Ordinary Shares

Operations

- Highly experienced management, clinical and regulatory team
- Leading KOLs serve on CAB
- Successful corporate partnerships and licensing deals

Short Term Milestones

Data Release from Namodenoson Phase II Clinical Studies*:		
1.	**Q1/2019**	**Phase II Advanced Liver Cancer (Fast track and Orphan Status)**
2.	**Q3/2019**	**Phase II NASH Study**

*Estimated timelines

From Concept to Technology



Company platform technology mimics natural body mechanism to combat cancer and inflammation

Drug Development Pipeline

Drug	Pre-clinical	Phase I	Phase II	Phase III	Market
Piclidenoson – Autoimmune inflammatory Diseases					
• Rheumatoid Arthritis				Ongoing	~$35B
• Psoriasis				Ongoing	~$11.4B
Namodenoson – Liver Diseases					
• Liver Cancer			Phase II Results Q1/19		~$1.4B
• NASH			Phase II Results Q3/2019		~$35B
CF602					
• Erectile Dysfunction		Ongoing			~$3.2B

**Sources: Visiongain estimates global psoriasis drug market will be $11.4bB by 2020 and the global rheumatoid arthritis drug market will be $34.6B by 2020; Datamonitor estimates the HCC drug market at $1.4B in 2019; Grand View Research estimates the global erectile dysfunction drug market at $3.2B by 2022; Deutsche Bank* puts the peak market for NASH therapies at $35B to $40B by 2025.

Corporate Partnerships - Out-licensing deals

~$16 million* upfront and milestone payments received to date

KWANG DONG PHARMACEUTICAL CO.,LTD. [Trades on South Korean Stock Exchange (Ticker: A009290)]

- Exclusive regional license to develop and commercialize Piclidenoson for the treatment of rheumatoid arthritis in Korea

cipher PHARMACEUTICALS INC [Trades on TSX: (Ticker: CPH)]

- Exclusive regional license to distribute Piclidenoson for the treatment of rheumatoid arthritis and moderate to severe psoriasis in Canada

Chong Kun Dang Pharm. Seoul, Korea [Traded on South Korean Stock Exchange (Ticker: 185750)]

- Exclusive distribution agreement in South Korea for distribution of Namodenoson for treatment of liver cancer

Gebro Pharma [privately-own company]

- Exclusive regional license to distribute Piclidenoson for the treatment of rheumatoid arthritis and moderate to severe psoriasis in Spain, Switzerland and Austria

CMS 康哲药业 CHINA MEDICAL SYSTEM [Trades on Hong Kong Stock Exchange (Ticker: 867)]

- Exclusive regional license to develop, register & market Piclidenoson & Namodenoson in China, Hong Kong, Macao and Taiwan.

$8.5M was from a license with a Japanese company, SKK; the license was terminated due to SKK's strategic change of focus to indications not related to autoimmune diseases

Piclidenoson – Anti-Inflammatory Drug



Piclidenoson

Rheumatoid Arthritis & Psoriasis

Mechanism of Action



(NYSE American: CANF) (TASE:CFBI)

CANFITE BioPharma Ltd.

Rheumatoid Arthritis - Phase IIb Data

Phase IIb study, Placebo controlled; 79 patients – Positively concluded

All Patients



Patients with No Prior Systemic Therapy*



*MTX, Biological Drugs

CANFITE BioPharma Ltd.

Rheumatoid Arthritis - Phase III Study Ongoing

ACRobat – Can-Fite's Phase III clinical study is designed to establish Piclidenoson as non-inferior to MTX in newly diagnosed patients with moderate-to-severe RA This Protocol is in Agreement with EMA

- Randomized, double-blind, active and placebo-controlled
- 500 patients to be enrolled in Europe, Canada and Israel
- Primary endpoint will be Disease Activity Score (DAS) of Low Disease Activity (LDA) at week 12
- Secondary endpoints will include proportion of subjects achieving DAS remission; 24 week total duration
- Correlation between A3AR expression and response to Piclidenoson will be analyzed
- Patient enrollment ongoing



Psoriasis Phase II/III Data vs. Celgene's Otezla*

- **Phase II/III study did not achieve the primary endpoint of PASI 75 at 12 weeks**
- **Otezla® sales were $1.3 billion in 2017, 26% increase over 2016[1]**
- **Peak Otezla® sales estimated at $2.35 billion in 2020[2]**









Sources: 1) Celgene 2017 annual report 2) DrugAnalyst, Ltd.

*Comparisons are derived from reported Otezla Phase 3 data vs. Piclidenoson Phase 2 data and are not an actual head-to-head clinical trial. If this were a head-to-head clinical trial, outcomes may be different.

CANFITE BioPharma Ltd.

Psoriasis Phase III Study - Ongoing

Comfort – Phase III clinical study is designed to establish Piclidenoson superiority vs. placebo and non-inferiorty vs. Otezla in patients with moderate-to-severe Plaque Psoriasis

This Protocol is in Agreement with EMA

- Randomized, double-blind, active and placebo-controlled
- 407 patients to be enrolled in Europe, Canada and Israel
- Primary endpoint is PASI 75 at week 16 vs. placebo
- Secondary endpoints include non-inferiority vs. Otezla at week 32
- Patients will be selected to the study based on over expression of the A3AR biomarker
- 32 week total duration; optional extension to 48 week



Namodenoson – Liver Disease Drug



Namodenoson

Advanced Liver Cancer & NASH

Mechanism of Action



(NYSE American: CANF) (TASE:CFBI)

CANFITE BioPharma Ltd.

Namodenoson for the Treatment of Liver Cancer

Phase I/II Positive Results

- Excellent safety profile and lack of hepatotoxicity
- Prolongation of survival time
- Regression of skin tumor metastases
- Stable disease (22%)



Regulatory Status

- FDA and EMA have granted **Orphan Drug** status
- FDA granted **Fast Track** status as a second line treatment

*Da Fonseca LG et al, 2015; Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol. 2015 Jul;3(4):793-796ma.

Liver Cancer - Phase II Study Completed Enrollment

Data expected to be released Q1 2019

Phase II - Study Protocol

- Second-Line Treatment
- Advanced Hepatocellular Carcinoma; Child-Pugh B
- 78 patients
- US, Europe and Israel
- Primary end point: overall survival
- Patient enrollment completed August 2017
- Currently following survival data and will perform survival analysis at earliest possible opportunity



Namodenoson for the Treatment of NASH

"America's Greatest Health Risk" – *Scientific American, 2015*

- ✓ 17% - 33% Prevalence of NAFLD in the U.S.[1]
- ✓ 2-5% of U.S. Population has NASH[2]
- ✓ 3rd Leading Cause of Liver Transplant in U.S. & on Trajectory to Become Leading Cause[3]
- ✓ $35-40 Billion Market by 2025[4]



Sources: 1) Study published in Hepatology, 2) NIH, 3) Study published in Gastroenterology, 4) Deutsche Bank

NASH – Excellent Pre-clinical Data

Namodenoson markedly improved liver function & pathology in NASH experimental models (STAM & CCL4)

- ✓ **Anti-inflammatory** - Namodenoson reduces NAFLD Activity Score (NAS) in STAM model
- ✓ **Anti-Fibrotic effect** - in vitro and in the CCL4 model
- ✓ **Anti steatotic effect** - Significant decrease in steatosis, ballooning and lobular inflammation (STAM)
- ✓ **ALT** - a decrease in plasma ALT and triglyceride levels (STAM & CCL4)
- ✓ **Liver protective effect** - Protects the liver against Ischemia/Reperfusion injury

Robust Decrease in ALT



NASH – Phase II Study

Data expected to be released Q3 2019

- **Multicenter,** randomized, double-blinded, placebo-controlled, dose-finding efficacy and safety study
- 60 patients with NAFLD with or without NASH
- **Primary end point**: mean percent change from baseline in serum alanine aminotransferase (ALT) levels and safety
- **Secondary end point**: % change from Baseline in hepatic steatosis measured by magnetic resonance imaging-determined proton-density fat-fraction (MRI-PDFF)



Leading KOLs (**Dr. Freidman**; Mount Sinai, **Dr. Arun Sanyal**; Virginia University, **Dr. Safadi**; Hadassah Jerusalem), on SAB and have advised on protocol design

Spotlight on Milestones

- **Namodenoson:**
  - ➢ Liver Cancer Phase II data (~$1.4B Opportunity) **Q1 2019**
  - ➢ NAFLD/NASH (~$35B Opportunity) **Q3 2019**
- **Piclidenoson:**
  - ➢ Rheumatoid Arthritis (~$35B Opportunity) **Ongoing**
  - ➢ Psoriasis (~$11.4B Opportunity) **Ongoing**

**Sources: Visiongain estimates global psoriasis drug market will be $11.4 by 2020 and the global rheumatoid arthritis drug market will be $34.6b by 2020; Datamonitor estimates the HCC drug market at $1.4 b in 2019; Grand View Research estimates the global erectile dysfunction drug market at $3.2b by 2022; Deutsche Bank* puts the peak market for NASH therapies at $35 b to $40 b by 2025.